Catalent has the broadest drug development toolkit, offering clients multiple technologies to enhance the bioavailability and solubility of drugs during formulation.
Micronisation is a proven, dependable and versatile method to achieve high quality particle size reduction to assist in API and formulation optimisation. Catalent Micron Technologies is a global leader in particle size reduction services, delivering high quality micronisation, milling, and analytical services. Its full range of capabilities includes:
• Development through to commercial scale
• Micronisation (jet mill)
• Mechanical milling (hammer mill, pin mill)
• Cryogenic milling
• Controlled handling of potent and cytotoxic compounds
• Comprehensive supporting analytical services
Spray drying can also assist in overcoming formulation and development challenges, and from its facility in San Diego, Catalent offers this service from early phase development through to clinical manufacturing scale. With over 75 years’ experience in spray drying and amorphous dispersion technology, the Pharmatek SD spray drying team can fully characterise an API and associated formulations throughout feasibility, development, and commercialisation, to provide a robust data package in support of regulatory filings.
The Pharmatek SD spray drying technology offered by Catalent is integrated into its extended OptiForm Solution Suite platform, which allows drug developers to gain an insight into accelerating programmes from late-stage discovery to phase I trials.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.